Natalizumab may improve cognition and mood in multiple sclerosis

• Published in: European neurology Vol. 67; no. 3; p. 162
• Main Authors: Lang, C, Reiss, C, Mäurer, M
• Format: Journal Article
• Language: English
• Published: Switzerland 01-03-2012
• Subjects: Adult; Affect - drug effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Attention - drug effects; Cognition - drug effects; Cognition Disorders - drug therapy; Cognition Disorders - etiology; Cognition Disorders - psychology; Female; Humans; Male; Memory - drug effects; Middle Aged; Multiple Sclerosis - complications; Multiple Sclerosis - drug therapy; Multiple Sclerosis - psychology; Natalizumab; Neuropsychological Tests; Prospective Studies
• ISSN: 1421-9913
• DOI: 10.1159/000334722

Immunomodulating therapies may prevent relapses in multiple sclerosis and stabilize neurological status. However, little is known about the influence particularly of newer drugs on cognitive functions. We conducted an open-label prospective study to demonstrate whether natalizumab is apt to improve cognitive functions and mood in 29 patients tested psychometrically while under treatment for 6 months. We found improvements in some measures of attention, memory, mood, and well-being, but no deterioration, although patients suffered from their diseases for more than 10 years and had an EDSS score of 3.5. It is concluded that natalizumab is able to stabilize or improve cognition and mood even in longer-lasting multiple sclerosis.